Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Profit After Tax (2020 - 2026)

Barinthus Biotherapeutics filings provide 7 years of Profit After Tax readings, the most recent being -$5.5 million for Q1 2026.

  • On a quarterly basis, Profit After Tax rose 71.86% to -$5.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$52.3 million, a 19.79% increase, with the full-year FY2025 number at -$66.5 million, down 8.82% from a year prior.
  • Profit After Tax hit -$5.5 million in Q1 2026 for Barinthus Biotherapeutics, up from -$11.1 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $15.7 million in Q2 2022 to a low of -$23.8 million in Q2 2023.
  • Median Profit After Tax over the past 5 years was -$15.5 million (2024), compared with a mean of -$11.8 million.
  • Biggest five-year swings in Profit After Tax: soared 280.35% in 2022 and later crashed 807.96% in 2023.
  • Barinthus Biotherapeutics' Profit After Tax stood at -$21.2 million in 2022, then increased by 18.39% to -$17.3 million in 2023, then fell by 18.78% to -$20.5 million in 2024, then skyrocketed by 45.86% to -$11.1 million in 2025, then soared by 50.26% to -$5.5 million in 2026.
  • The last three reported values for Profit After Tax were -$5.5 million (Q1 2026), -$11.1 million (Q4 2025), and -$14.6 million (Q3 2025) per Business Quant data.